Open AccessPrognostic value of platelet to lymphocyte ratio in predicting survival of patients with metastatic castration‐resistant prostate cancer receiving abiraterone acetate: An evidence‐based case report and review of literature
Author(s) -
Yausep Oliver E.,
Agarwal Raksheeth,
Aulina Rifqha,
Wijaya Anthony E.,
Amaia Ilonka,
Moekti Addina W.,
Rinaldi Ikhwan,
Hamid Agus Rizal A. H.
Publication year - 2019
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.2288
Subject(s) - abiraterone acetate , medicine , prostate cancer , oncology , platelet , overall survival , castration , cancer , androgen deprivation therapy , urology , hormone
Platelet to lymphocyte ratio (PLR) is a candidate prognostic marker for metastatic castration‐resistant prostate cancer patients receiving abiraterone acetate and evidence demonstrates that a high PLR is associated with poor survival. More studies are required to verify current findings and establish a definite cutoff point.